Literature DB >> 7472505

Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments.

M Nibuya1, S Morinobu, R S Duman.   

Abstract

The influence of chronic electroconvulsive seizure (ECS) or antidepressant drug treatments on expression of brain-derived neurotrophic factor (BDNF) and its receptor, trkB, was examined by in situ hybridization and Northern blot. In frontal cortex, acute ECS increased BDNF mRNA approximately twofold, an effect significantly augmented by a prior course of chronic ECS treatment (10 d). In the hippocampus, the influence of chronic ECS varied between the major subfields. In the dentate gyrus granule cell layer, chronic ECS decreased the acute induction of BDNF and trkB mRNA by approximately 50%, but prolonged their expression: levels remained elevated two- to threefold 18 hr later after the last chronic ECS treatment, but returned to control 18 hr after acute ECS. In CA3 and CA1 pyramidal cell layers, chronic ECS significantly elevated the acute induction of BDNF, and tended to prolong the expression of BDNF and trkB mRNA. A similar effect was observed in layer 2 of the piriform cortex, where chronic ECS significantly increased the acute induction and prolonged the expression of BDNF and trkB mRNA. Chronic (21 d), but not acute (1 d), administration of several different antidepressant drugs, including tranylcypromine, sertraline, desipramine, or mianserin, significantly increased BDNF mRNA and all but mianserin increased trkB mRNA in hippocampus. In contrast, chronic administration of nonantidepressant psychotropic drugs, including morphine, cocaine, or haloperidol, did not increase levels of BDNF mRNA. Furthermore, chronic administration of ECS or antidepressant drugs completely blocked the down-regulation of BDNF mRNA in the hippocampus in response to restraint stress. The enhanced induction and prolonged expression of BDNF in response to chronic ECS and antidepressant drug treatments could promote neuronal survival, and protect neurons from the damaging effects of stress.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7472505      PMCID: PMC6578063     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  532 in total

1.  Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system.

Authors:  C Cirelli; G Tononi
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

2.  Role for GDNF in biochemical and behavioral adaptations to drugs of abuse.

Authors:  C J Messer; A J Eisch; W A Carlezon; K Whisler; L Shen; D H Wolf; H Westphal; F Collins; D S Russell; E J Nestler
Journal:  Neuron       Date:  2000-04       Impact factor: 17.173

3.  Antidepressant use during pregnancy.

Authors:  P Boksa
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

Review 4.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

5.  Neuroprotective effects of antidepressant and mood stabilizing drugs.

Authors:  L Trevor Young
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

6.  Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders.

Authors:  Pierre Sokoloff; Olivier Guillin; Jorge Diaz; Patrick Carroll; Nathalie Griffon
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

7.  Epigenetic dysregulation of Oxtr in Tet1-deficient mice has implications for neuropsychiatric disorders.

Authors:  Aaron J Towers; Martine W Tremblay; Leeyup Chung; Xin-Lei Li; Alexandra L Bey; Wenhao Zhang; Xinyu Cao; Xiaoming Wang; Ping Wang; Lara J Duffney; Stephen K Siecinski; Sonia Xu; Yuna Kim; Xiangyin Kong; Simon Gregory; Wei Xie; Yong-Hui Jiang
Journal:  JCI Insight       Date:  2018-12-06

8.  Decreased serum BDNF levels in patients with epileptic and psychogenic nonepileptic seizures.

Authors:  W C LaFrance; K Leaver; E G Stopa; G D Papandonatos; A S Blum
Journal:  Neurology       Date:  2010-10-05       Impact factor: 9.910

9.  Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.

Authors:  Kazuko Sakata; Abigail E Overacre
Journal:  J Neurochem       Date:  2017-08-16       Impact factor: 5.372

10.  The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study.

Authors:  Maria Neves-Pereira; Emanuela Mundo; Pierandrea Muglia; Nicole King; Fabio Macciardi; James L Kennedy
Journal:  Am J Hum Genet       Date:  2002-08-02       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.